| Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. Graff J.R., Konicek B.W., Vincent T.M., Lynch R.L., Monteith D., Weir S.N., Schwier P., Capen A., Goode R.L., Dowless M.S. et al.
J. Clin. Invest. 117:2638-2648(2007) · Mapped (6) |
| Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Carter B.Z., Mak D.H., Shi Y., Schober W.D., Wang R.Y., Konopleva M., Koller E., Dean N.M., Andreeff M.
Cell Cycle 5:2223-2229(2006) · Mapped (3) |
| Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide. Vickers T.A., Zhang H., Graham M.J., Lemonidis K.M., Zhao C., Dean N.M.
J. Immunol. 176:3652-3661(2006) · Mapped (18) |
| Identification of novel PPARgamma target genes in primary human adipocytes. Perera R.J., Marcusson E.G., Koo S., Kang X., Kim Y., White N., Dean N.M.
Gene 369:90-99(2006) · UniProtKB (1) |
| Protein phosphatase 5 is required for ATR-mediated checkpoint activation. Zhang J., Bao S., Furumai R., Kucera K.S., Ali A., Dean N.M., Wang X.F.
Mol. Cell. Biol. 25:9910-9919(2005) · Mapped (9) |
| Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Golden T., Aragon I.V., Zhou G., Cooper S.R., Dean N.M., Honkanen R.E.
Cancer Lett. 215:95-100(2004) · Mapped (2) |
| Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Carter B.Z., Milella M., Tsao T., McQueen T., Schober W.D., Hu W., Dean N.M., Steelman L., McCubrey J.A., Andreeff M.
Leukemia 17:2081-2089(2003) · Mapped (4) |
| Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. Urban G., Golden T., Aragon I.V., Cowsert L., Cooper S.R., Dean N.M., Honkanen R.E.
J. Biol. Chem. 278:9747-9753(2003) · Mapped (40) |
| Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Derenne S., Monia B., Dean N.M., Taylor J.K., Rapp M.J., Harousseau J.L., Bataille R., Amiot M.
Blood 100:194-199(2002) · Mapped (12) |
| Protein kinase Cdelta overexpression enhances radiation sensitivity via extracellular regulated protein kinase 1/2 activation, abolishing the radiation-induced G(2)-M arrest. Lee Y.J., Soh J.W., Dean N.M., Cho C.K., Kim T.H., Lee S.J., Lee Y.S.
Cell Growth Differ. 13:237-246(2002) · UniProtKB (1) · Mapped (10) |
| 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Taylor V., Wong M., Brandts C., Reilly L., Dean N.M., Cowsert L.M., Moodie S., Stokoe D.
Mol. Cell. Biol. 20:6860-6871(2000) · UniProtKB (1) |
| Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. Shen L., Dean N.M., Glazer R.I.
Mol. Pharmacol. 55:396-402(1999) · UniProtKB (1) |
| Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Geiger T., Muller M., Dean N.M., Fabbro D.
Anticancer Drug Des. 13:35-45(1998) · Mapped (3) |
| Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Dean N.M., McKay R.
Proc. Natl. Acad. Sci. U.S.A. 91:11762-11766(1994) · Mapped (3) |
